How many stocks are there of NanoRepro?
The current number of stocks of NanoRepro is 12.9 M undefined.
NanoRepro Stocks 2025
NanoRepro Stocks
12.9 M
Ticker
NN6.DE
ISIN
DE0006577109
WKN
657710
In 2025, NanoRepro had 12.9 M outstanding stocks, a -0.03% change from the 12.9 M stocks in the previous year.
The NanoRepro Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2022 | 12.9 |
| 2021 | 12.9 |
| 2020 | 9.33 |
| 2019 | 8.65 |
| 2018 | 8.65 |
| 2017 | 7.13 |
| 2016 | 5.89 |
| 2015 | 4.52 |
| 2014 | 3.43 |
| 2013 | 3.12 |
| 2012 | 2.42 |
| 2011 | 1.23 |
| 2010 | 1.23 |
| 2009 | 1.26 |
| 2007 | 1.13 |
| 2006 | 1.13 |
| 2005 | 1.13 |
NanoRepro shares outstanding DE0006577109 · 657710
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue NanoRepro earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates NanoRepro's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of NanoRepro’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating NanoRepro's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2005 | 1.13 M Aktien |
| 2006 | 1.13 M Aktien |
| 2007 | 1.13 M Aktien |
| 2009 | 1.26 M Aktien |
| 2010 | 1.23 M Aktien |
| 2011 | 1.23 M Aktien |
| 2012 | 2.42 M Aktien |
| 2013 | 3.12 M Aktien |
| 2014 | 3.43 M Aktien |
| 2015 | 4.52 M Aktien |
| 2016 | 5.89 M Aktien |
| 2017 | 7.13 M Aktien |
| 2018 | 8.65 M Aktien |
| 2019 | 8.65 M Aktien |
| 2020 | 9.33 M Aktien |
| 2021 | 12.9 M Aktien |
| 2022 | 12.9 M Aktien |
NanoRepro Aktienanalyse
What does NanoRepro do?
The Nanorepro AG was founded in 1998 in Marburg an der Lahn and has since developed into a leading company in the development and production of diagnostic rapid tests and self-tests. The company has been listed on the Frankfurt Stock Exchange since 2006 and has its headquarters in the university city of Marburg. Nanorepro's business model focuses on the production and distribution of innovative, reliable, and easy-to-use self-tests for the medical field. The company concentrates on the practical application of the tests - they should be simple, fast, and user-friendly. Nanorepro's core competence lies in the design, production, and distribution of rapid tests and self-tests for the medical field. The company relies on close cooperation with other companies and research institutions to continuously improve the tests and develop new products. Nanorepro focuses on various areas, including the manufacturing of rapid tests and self-tests for the diagnosis of infectious diseases. In addition, the company also offers tests to check pregnancy status or determine ovulation. Nanorepro's range of products also includes self-tests for the early detection of diseases such as diabetes. With its wide range of products, the company is able to address a large customer base and achieve a positive market position. One key product of Nanorepro is the early pregnancy test. This product is easy to handle and allows women to quickly and safely determine if they are pregnant or not. Nanorepro also offers an ovulation test to help women determine the timing of ovulation. Another test offered by the company is the Lyme borreliosis self-test, which allows for the detection of antibodies to Lyme borreliosis. Nanorepro also offers numerous tests for diagnosing infectious diseases. These include tests that can diagnose bacterial or viral infections such as streptococcal infections or hepatitis B and C. The tests are highly accurate and reliable, enabling quick diagnosis and treatment. Another area in which Nanorepro is expanding is the development of self-tests for the early detection of cancer. For this purpose, the company works closely with scientific and research institutions to continuously improve the tests and make them even more precise and reliable. Nanorepro places a strong emphasis on quality control and safety in the production of the tests. The products are CE-certified, ensuring high quality and safety for the user. In addition, the company has been certified according to the standards of the International Quality Management System ISO 13485, guaranteeing a high standard in the production and marketing of medical devices. Overall, Nanorepro AG has established itself as a leading company in the field of rapid tests and self-tests. With its wide range of products and constant willingness to innovate, the company is able to quickly and effectively respond to the requirements of customers and partners. The company's extensive experience in the field of medical diagnostics contributes to Nanorepro being perceived as a reliable partner in medical technology. NanoRepro ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating NanoRepro's Shares Outstanding
NanoRepro's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in NanoRepro’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding NanoRepro’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in NanoRepro’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about NanoRepro stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of NanoRepro are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of NanoRepro evolved in recent years?
The number of shares of NanoRepro has increased by -0.03% gesunken compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. NanoRepro as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of NanoRepro?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does NanoRepro pay?
Over the past 12 months, NanoRepro paid a dividend of 0.5 EUR . This corresponds to a dividend yield of about 37.04 %. For the coming 12 months, NanoRepro is expected to pay a dividend of 0.5 EUR.
What is the dividend yield of NanoRepro?
The current dividend yield of NanoRepro is 37.04 %.
When does NanoRepro pay dividends?
NanoRepro pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of NanoRepro?
NanoRepro paid dividends every year for the past 1 years.
What is the dividend of NanoRepro?
For the upcoming 12 months, dividends amounting to 0.5 EUR are expected. This corresponds to a dividend yield of 37.04 %.
In which sector is NanoRepro located?
NanoRepro is assigned to the 'Health' sector.
Wann musste ich die Aktien von NanoRepro kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of NanoRepro from 6/20/2023 amounting to 0.15 EUR, you needed to have the stock in your portfolio before the ex-date on 6/16/2023.
When did NanoRepro pay the last dividend?
The last dividend was paid out on 6/20/2023.
What was the dividend of NanoRepro in the year 2024?
In the year 2024, NanoRepro distributed 0 EUR as dividends.
In which currency does NanoRepro pay out the dividend?
The dividends of NanoRepro are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The NanoRepro stock can be added to a savings plan with the following providers: ING
Andere Kennzahlen von NanoRepro
Our stock analysis for NanoRepro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NanoRepro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
